Impact of solriamfetol treatment on sleep quality in Chinese patients with OSA-EDS: results of a randomized controlled trial [PDF]
Frontiers in MedicineIntroductionWake-promoting agents (WPAs), such as solriamfetol, have emerged as effective treatment options for treating excessive daytime sleepiness (EDS) in patients with obstructive sleep apnea (OSA).
Fen Wang +7 more
doaj +2 more sources
Solriamfetol impurities: Synthesis, characterization, and analytical method (UPLC-UV) validation [PDF]
Journal of Pharmaceutical Analysis, 2023 Given that impurities may affect the quality and safety of drug products, impurity identification and profiling is an integral part of drug quality control and is particularly important for newly developed medications such as solriamfetol, which is used ...
Nafisah Al-Rifai +6 more
doaj +2 more sources
Post-marketing safety of solriamfetol: A retrospective pharmacovigilance study based on the us food and drug administration adverse event reporting system. [PDF]
PLoS ONEPurposeExcessive daytime sleepiness (EDS) seriously affects quality of life and may increase the risk of life-threatening situations, such as motor vehicle accidents.
Lingling Wu, Kaijian Zhu
doaj +2 more sources
Comparative efficacy of new wake-promoting agents for narcolepsy-a network meta-analysis [PDF]
BMC NeurologyBackground As a rare sleep disorder, narcolepsy is treated with various therapeutic options. This article systematically analyzes the efficacy and safety of novel approved wake-promoting drugs.
Zian Yan +5 more
doaj +2 more sources
Comparative Efficacy and Safety of Multiple Wake-Promoting Agents for the Treatment of Excessive Daytime Sleepiness in Narcolepsy: A Network Meta-Analysis [PDF]
Nature and Science of Sleep, 2023 Shuqin Zhan,1 Hui Ye,2 Ning Li,1 Yimeng Zhang,1 Yueyang Cheng,1 Yuanqing Wang,1,3 Shimin Hu,1 Yue Hou1 1Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, 100053, People’s Republic of China; 2Ignis Therapeutics (Shanghai ...
Zhan S +7 more
doaj +2 more sources
Comparative efficacy, safety and benefit/risk of alerting agents for excessive daytime sleepiness in patients with obstructive sleep apnoea: a network meta-analysisResearch in context [PDF]
EClinicalMedicineSummary: Background: Obstructive sleep apnoea (OSA) is a common chronic respiratory disease associated with a high burden of disabilities related to sleepiness and reduced quality of life.
Jean-Louis Pépin +11 more
doaj +2 more sources
Evaluation of pitolisant, sodium oxybate, solriamfetol, and modafinil for the management of narcolepsy: a retrospective analysis of the FAERS database [PDF]
Frontiers in PharmacologyObjectiveNarcolepsy, a rare neurological disorder believed to have an autoimmune etiology, necessitates lifelong management. This study aimed to provide evidence supporting the safety of pharmacological treatment for narcolepsy.MethodsFive-year data on ...
Xiaodan Zhou +5 more
doaj +2 more sources
Effect of sleep apnoea interventions on multiple health outcomes: an umbrella review of meta-analyses of randomised controlled trialsResearch in context [PDF]
EClinicalMedicineSummary: Background: Obstructive sleep apnoea (OSA) is a prevalent chronic condition that is associated with cardiometabolic and neurocognitive complications.
Camille Figard +7 more
doaj +2 more sources
Comorbidity of obstructive sleep apnea and narcolepsy: A challenging diagnosis and complex management [PDF]
Sleep Medicine: XIntroduction: Narcolepsy and obstructive sleep apnea syndrome (OSA) are relevant causes of excessive daytime sleepiness (EDS); although different for etiopathogenesis and symptoms, differential diagnosis is sometimes difficult, and guidelines are lacking
Silvia Miano +2 more
doaj +2 more sources
A Review of Current and Future Pharmacologic Treatments for Narcolepsy [PDF]
European PsychiatryIntroduction Narcolepsy is a rare but disabling neurological disorder involving disruption of the sleep-wake cycle that is often under- or misdiagnosed (Barateau L, et al. J Sleep Res. 2022;31(4):e13631).
P. Chue +4 more
doaj +2 more sources